195 related articles for article (PubMed ID: 30908997)
1. In-silico designing and characterization of binding modes of two novel inhibitors for CB1 receptor against obesity by classical 3D-QSAR approach.
Khan N; Halim SA; Khan W; Zafar SK; Ul-Haq Z
J Mol Graph Model; 2019 Jun; 89():199-214. PubMed ID: 30908997
[TBL] [Abstract][Full Text] [Related]
2. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
Floresta G; Apirakkan O; Rescifina A; Abbate V
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
[TBL] [Abstract][Full Text] [Related]
3. Computational Analysis of CRTh2 receptor antagonist: A Ligand-based CoMFA and CoMSIA approach.
Babu S; Sohn H; Madhavan T
Comput Biol Chem; 2015 Jun; 56():109-21. PubMed ID: 25935115
[TBL] [Abstract][Full Text] [Related]
4. Active site characterization and structure based 3D-QSAR studies on non-redox type 5-lipoxygenase inhibitors.
Ul-Haq Z; Khan N; Zafar SK; Moin ST
Eur J Pharm Sci; 2016 Jun; 88():26-36. PubMed ID: 27044904
[TBL] [Abstract][Full Text] [Related]
5. Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity.
Sharma MK; Murumkar PR; Giridhar R; Yadav MR
Mol Divers; 2015 Nov; 19(4):871-93. PubMed ID: 26183840
[TBL] [Abstract][Full Text] [Related]
6. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
7. 3D QSAR pharmacophore, CoMFA and CoMSIA based design and docking studies on phenyl alkyl ketones as inhibitors of phosphodiesterase 4.
Gaurav A; Singh R
Med Chem; 2012 Sep; 8(5):894-912. PubMed ID: 22741782
[TBL] [Abstract][Full Text] [Related]
8. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
[TBL] [Abstract][Full Text] [Related]
10. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T
J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177
[TBL] [Abstract][Full Text] [Related]
11. Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.
Romero-Parra J; Chung H; Tapia RA; Faúndez M; Morales-Verdejo C; Lorca M; Lagos CF; Di Marzo V; David Pessoa-Mahana C; Mella J
Eur J Pharm Sci; 2017 Apr; 101():1-10. PubMed ID: 28137469
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
Salo OM; Savinainen JR; Parkkari T; Nevalainen T; Lahtela-Kakkonen M; Gynther J; Laitinen JT; Järvinen T; Poso A
J Med Chem; 2006 Jan; 49(2):554-66. PubMed ID: 16420041
[TBL] [Abstract][Full Text] [Related]
13. Studies of tricyclic piperazine/piperidine furnished molecules as novel integrin αvβ3/αIIbβ3 dual antagonists using 3D-QSAR and molecular docking.
Yan Y; Li Y; Zhang S; Ai C
J Mol Graph Model; 2011 Feb; 29(5):747-62. PubMed ID: 21273104
[TBL] [Abstract][Full Text] [Related]
14. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Sivan SK; Manga V
J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
[TBL] [Abstract][Full Text] [Related]
15. CoMFA and CoMSIA studies on 5-hydroxyindole-3-carboxylate derivatives as 5-lipoxygenase inhibitors: generation of homology model and docking studies.
Aparoy P; Suresh GK; Kumar Reddy K; Reddanna P
Bioorg Med Chem Lett; 2011 Jan; 21(1):456-62. PubMed ID: 21084193
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
Dessalew N; Patel DS; Bharatam PV
J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
[TBL] [Abstract][Full Text] [Related]
17. 3D QSAR studies, pharmacophore modeling and virtual screening on a series of steroidal aromatase inhibitors.
Xie H; Qiu K; Xie X
Int J Mol Sci; 2014 Nov; 15(11):20927-47. PubMed ID: 25405729
[TBL] [Abstract][Full Text] [Related]
18. Design of novel dopamine D
Zhang C; Li Q; Meng L; Ren Y
J Biomol Struct Dyn; 2020 Feb; 38(3):860-885. PubMed ID: 30916624
[TBL] [Abstract][Full Text] [Related]
19. Investigation on quantitative structure activity relationships and pharmacophore modeling of a series of mGluR2 antagonists.
Zhang MQ; Zhang XL; Li Y; Fan WJ; Wang YH; Hao M; Zhang SW; Ai CZ
Int J Mol Sci; 2011; 12(9):5999-6023. PubMed ID: 22016641
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
Dessalew N; Singh SK
Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
